Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Generic Drugs

FDA Announces Two Steps to Increase Drug Competition for Improved Patient Access

Washington, DC, August 2, 2017 — The U.S. Food and Drug Administration (FDA) on June 27 announced it is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives.

The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review of generic drug applications where competition is limited.

These actions are among the first taken under the agency’s Drug Competition Action Plan, announced by FDA Commissioner Scott Gottlieb in late May. Continue reading

PhRMA: New Study Further Confirms Increased Use of Generics After Part D

Washington, DC, April 2, 2017Pharmaceutical Research and Manufacturers of America (PhRMA) has written a lot about how things have changed since 2006 and the implementation of Part D.

PhRMA has looked at how Part D costs less than originally projected, how premiums have remained steady and how competition has worked to keep costs low.

In addition, PhRMA has highlighted what the Medicare Trustees report has shown, that there has been a steady increase year after year in the generic utilization rate for Part D beneficiaries. Continue reading

Generic Pharmaceutical Association Changes Name to Association for Accessible Medicines; Launches Education Campaign

Washington, DC, February 22, 2017 — The Generic Pharmaceutical Association (GPhA), the nation’s largest trade group representing generic pharmaceutical and biosimilar companies, on February 14 week unveiled a new national effort to contain the cost of prescription medicines.

The group is becoming the Association for Accessible Medicines (AAM) to communicate its mission to make more medicines more accessible to more people who need them. Continue reading

Report: Generic Drug Savings Reached $227 Billion in 2015

gpha-twitterWashington, DC, October 20, 2016 — Annual savings from generic prescription drugs increased 328 percent from 2005-2016, according to the new 2016 Generic Drug Savings and Access in the United States report, compiled by the QuintilesIMS Institute on behalf of the Generic Pharmaceutical Association (GPhA).

This report confirms again that generic drugs are essential to reducing health costs and play a critical role in growing patient access.

“Generic drugs are the foundation of any successful effort to lower health spending and increase patient access to affordable medicine,” said Chip Davis, President and CEO, GPhA. Continue reading

Kaiser Health News: EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog

Generic 1Washington, DC, September 6, 2016 — Sydney Lupkin reports on Kaiser Health News website that consumers and Congress members pushing for cheaper alternatives to the EpiPen and other high-priced drugs are seeking answers about a stubborn backlog of generic drug applications at the Food and Drug Administration that still stretches almost four years.

As of July 1, the FDA had 4,036 generic drug applications awaiting approval, and the median time it takes for the FDA to approve a generic is now 47 months, according to the Generic Pharmaceutical Association (GPhA).

The FDA has approved more generics the past few years, but a flood of new applications has steadily added to the demand. Continue reading

Pharmalot: FDA Continues to Struggle with Backlog of Generic Drug Applications

STAT PharmalotBoston, MA, March 3, 2016 ― Pharmalot reporter-blogger Ed Silverman reports in STAT that, under pressure to speed approval of generic medicines, the Food and Drug Administration (FDA) last week released data to defend its progress.

And while industry watchers say the statistics indicate the agency is making headway, there are also clear signs the FDA continues to struggle with the workload.

On the bright side, the number of full and tentative drug approvals has been rising each month since last April and reached 99 this past December, which is the largest tally ever issued in a single month, according to FDA watchers. Continue reading

Report: Generic Drugs Deliver a $254 Billion in Savings to U.S. Health Care System in 2014

Generic 1Washington, DC, December 14, 2015 ― The U.S. health care system saved a record $254 billion in 2014 from generic drugs, which amounts to $1.68 trillion over the most recent decade (2005-2014), according to the seventh annual Generic Drug Savings in the United States report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).

For the first time, this year’s report includes state-by-state savings from generics.

It also details the key role generic drugs play in Medicare and Medicaid savings, resulting in billions of dollars of savings to federal and state budgets, beneficiaries and taxpayers. Continue reading

GPhA Report: Generic Drugs Deliver a $254 Billion in Savings to 2014 U.S. Health Care System

Generic 1Washington, DC, December 5, 2015 ― The U.S. health care system saved a record $254 billion in 2014 from generic drugs, which amounts to $1.68 trillion over the most recent decade (2005-2014), according to the seventh annual Generic Drug Savings in the United States report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).

For the first time, this year’s report, released in November, includes state-by-state savings from generics.

It also details the key role generic drugs play in Medicare and Medicaid savings, resulting in billions of dollars of savings to federal and state budgets, beneficiaries and taxpayers. Continue reading

Governor Christie Signs Biosimilars Legislation

Chris Christie official portrait 2013Trenton, NJ, November 10, 2015 ― Legislation sponsored by Assembly Democrats Pamela Lampitt, Herb Conaway, Jr., M.D., Daniel Benson, Shavonda Sumter and Nancy Pinkin to make it easier for consumers to obtain more cost-effective, “generic” versions of biological medicines used to treat conditions such as rheumatoid arthritis, anemia, psoriasis and various forms of cancer has been signed into law.

“The FDA has created a safe pathway to make alternative biological medicines more readily available on the market,” said Lampitt (D-Camden, Burlington). “If there is a more cost-effective option to treat and cure various illnesses, then by all means we should be helping patients pursue it.” Continue reading

New Report Shows Generic Drugs Deliver a $254 Billion in Savings to U.S. Health Care System in 2014

Generic 1Washington, DC, November 4, 2015 ― The U.S. health care system saved a record $254 billion in 2014 from generic drugs, which amounts to $1.68 trillion over the most recent decade (2005-2014), according to the seventh annual Generic Drug Savings in the United States report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).

For the first time, this year’s report includes state-by-state savings from generics.

It also details the key role generic drugs play in Medicare and Medicaid savings, resulting in billions of dollars of savings to federal and state budgets, beneficiaries and taxpayers. Continue reading